H-ALA-TYR-PRO-GLY-LYS-PHE-NH2 Struktur

H-ALA-TYR-PRO-GLY-LYS-PHE-NH2

Bezeichnung:H-ALA-TYR-PRO-GLY-LYS-PHE-NH2

CAS-Nr352017-71-1

Englisch Name:H-ALA-TYR-PRO-GLY-LYS-PHE-NH2

CBNumberCB9174223

SummenformelC34H48N8O7

Molgewicht680.79

MOL-Datei352017-71-1.mol

H-ALA-TYR-PRO-GLY-LYS-PHE-NH2 physikalisch-chemischer Eigenschaften

Siedepunkt	1143.1±65.0 °C(Predicted)
Dichte	1.285±0.06 g/cm3(Predicted)
storage temp.	−20°C
Löslichkeit	Soluble in H2O
pka	9.84±0.15(Predicted)
Aggregatzustand	solid
Farbe	White to off-white
Wasserlöslichkeit	Soluble in water

Sicherheit

S-Sätze:	22-24/25
WGK Germany	3

H-ALA-TYR-PRO-GLY-LYS-PHE-NH2 Chemische Eigenschaften,Einsatz,Produktion Methoden

S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
Verwenden
AY-NH2 is used in the synthetic preparation of PAR4 agonist peptides towards PAR4 receptor activation.
Biologische Aktivität
ay-nh2 is a selective agonist of par4 with ec50 value of 11 μm [1].protease-activated receptor-4 (par4) is a member of pars and plays an important role in mediating cellular effects of thrombin through acting g-proteins i, 12/13 (rho and ras activation) and q (calcium signaling) [2].ay-nh2 is a potent par4 agonist and has a higher (~10 fold) activity than gypgkf-nh2. using rat platelet aggregation assay, it was shown that ay-nh2 had highly platelet aggregation ability than gy-nh2 and gf-nh2 [1]. when tested with platelet-rich plasma harvested from wild-type c57bl6 mice, ay-nh2 treatment exhibited highly agonist activity on par4 while had no effect on other pars [3].in male wistar rats model of paw oedema, i.pl. injection of ay-nh2 markedly reduced the nociceptive score in response to both noxious and non-noxious mechanical stimuli, thus inhibiting carrageenan-induced mechanical hyperalgesia and allodynia [4].
Lager
Store at -20°C
Einzelnachweise
[1]. hollenberg, m.d., et al., proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. br j pharmacol, 2004. 143(4): p. 443-54.
[2]. yu, g., et al., increased expression of protease-activated receptor 4 and trefoil factor 2 in human colorectal cancer. plos one, 2015. 10(4): p. e0122678.
[3]. faruqi, t.r., et al., structure-function analysis of protease-activated receptor 4 tethered ligand peptides. determinants of specificity and utility in assays of receptor function. j biol chem, 2000. 275(26): p. 19728-34.
[4]. asfaha, s., et al., protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. br j pharmacol, 2007. 150(2): p. 176-85.

H-ALA-TYR-PRO-GLY-LYS-PHE-NH2 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

352017-71-1, H-ALA-TYR-PRO-GLY-LYS-PHE-NH2 Verwandte Suche:

Send Inquriy